Trial Profile
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Goserelin; Leuprorelin; LHRH receptor agonists; Triptorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Aragon Pharmaceuticals; Johnson & Johnson
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium.
- 01 Oct 2019 Status changed from active, no longer recruiting to completed.
- 06 Apr 2018 Planned End Date changed from 31 Jan 2020 to 31 Dec 2019.